Request Deal Involvement
ESTEVE completed the acquisition of the HRA Pharma Rare Diseases business of Perrigo for €275m.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
financial advisors
Morgan Stanley
legal advisors
Wachtell Lipton Rosen & Katz
accounting advisors
Ernst & Young
financial advisors
Perella Weinberg Partners
legal advisors
Clifford Chance
or
Principals
target
PERRIGO COMPANY PLC (HRA PHARMA RARE DISEASES BUSINESS)
vendor
PERRIGO COMPANY PLC
bidder
ESTEVE
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite